Core B. Clinical Core

项目总结/摘要 临床核心 现在有大量的证据表明，阿尔茨海默病和相关疾病的病理学（统称为 称为AD）在临床症状发作前数十年开始。这个前驱期，临床前期，而 出现认知和功能沉默实际上与强大的变化有关，这些变化可以通过 这是一种生物标志物，为早期发现和干预提供了理想的机会。为此，我们采取了 领导开发和验证新颖和创新的临床认知行为测量，以确定 并将这些发现与最先进的生物标志物研究结合联合收割机。纽约大学ADC目前的研究 重点是NIA-AA阶段1至3的个体（特别关注主观记忆投诉，CSF和 成像生物标志物和身体功能）：临床前疾病、MCI和轻度AD与健康 老化（NIA-AA临床前阶段0）。临床核心的总体目标是提供准确的研究 对一组纵向随访的老年人进行尸检，以提供适当的受试者， 由ADC研究人员和合作科学家进行的研究项目的主题衍生材料。这 焦点直接服务于纽约大学ADC的主要研究主题：临床前AD的表征及其 向MCI和早期AD过渡。我们提出了8个具体目标：（1）维持和表征活跃的UDS队列 约400例患者（临床痴呆评分[CDR]<0.50%的队列）、MCI（CDR <0.530%的队列）或轻度 AD（CDR 0.5或队列的120%）;（2）招募、评估和留住来自不同领域的新参与者（~45） 背景，以补充队列的比例损耗损失;（3）提供文化敏感的招聘 策略和纵向研究评估;（4）收集、储存和分发CSF、血液和DNA 生物标本;（5）获得脑捐赠的同意;（6）提供适当的受试者、数据和生物标本 （7）整合数据收集和质量控制程序;（8）提供基础设施， 资源，并协调对NACC和其他国家和国际合作的贡献。通过提供 大量的标准化纵向临床、认知、生物标志物和神经影像学数据提供给研究者， 纽约大学ADC临床中心准备在提供必要的基础设施和资源方面发挥重要作用 促进我们对临床前AD及其向MCI和轻度AD症状阶段的过渡的理解。

PROJECT SUMMARY/ABSTRACT CLINICAL CORE There is now abundant evidence that the pathology of Alzheimer's disease and related disorders (collectively referred to as AD) begins decades before the onset of clinical symptoms. This prodromal, preclinical period, while appearing cognitively and functionally silent is in fact associated with robust changes that may be detected by biomarkers and presents an ideal opportunity for early detection and intervention. To do this, we have taken the lead in developing and validating novel and innovative clinical-cognitive-behavioral measurements to identify individuals at-risk and combine these findings with state-of-art biomarker studies. The NYU ADC current research focus is on individuals with NIA-AA Stages 1 to 3 (particular focus on subjective memory complaints, CSF and imaging biomarkers, and physical functionality): preclinical disease, MCI, and mild AD compared with healthy aging (NIA-AA preclinical stage 0). The overall goal of the Clinical Core is to provide accurate research diagnoses for a cohort of longitudinally followed older adults to autopsy to provide appropriate subjects and subject-derived materials for research projects conducted by ADC investigators and collaborating scientists. This focus directly serves the primary research theme of the NYU ADC: the characterization of preclinical AD and its transition to MCI and early AD. We propose 8 Specific Aims: (1) Maintain and characterize an active UDS cohort of ~400 individuals (Clinical Dementia Rating [CDR] 0 50% of cohort), MCI (CDR 0.5 30% of cohort), or mild AD (CDR 0.5 or 1 20% of cohort); (2) Recruit, assess, and retain new participants (~45) from diverse backgrounds to replenish the cohort in proportion to attritional losses; (3) Provide culturally-sensitive recruitment strategies and longitudinal research assessments; (4) Collect, store, and distribute CSF, blood, and DNA biospecimens; (5) Obtain consent for brain donations; (6) Provide appropriate subjects, data, and biospecimens for research studies; (7) Integrate data collection and quality control procedures; and (8) provide infrastructure, resources, and coordinate contribution to NACC and other national and international collaborations. By providing a wealth of standardized longitudinal clinical, cognitive, biomarker, and neuroimaging data to investigators, the NYU ADC Clinical Core is poised to play a significant role in providing the infrastructure and resources necessary to advance our understanding of preclinical AD and its transition to the symptomatic stages of MCI and mild AD.